0 CHECKOUT

Rabies - Pipeline Review, H1 2015

  • ID: 3266294
  • April 2015
  • 80 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Celltrion, Inc.
  • Humabs BioMed SA
  • Kamada Ltd.
  • NanoViricides, Inc.
  • PaxVax
  • Sanofi
  • MORE

Rabies - Pipeline Review, H1 2015

Summary

This, ‘Rabies - Pipeline Review, H1 2015’, provides an overview of the Rabies’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celltrion, Inc.
  • Humabs BioMed SA
  • Kamada Ltd.
  • NanoViricides, Inc.
  • PaxVax
  • Sanofi
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Rabies Overview
Therapeutics Development
Pipeline Products for Rabies - Overview
Pipeline Products for Rabies - Comparative Analysis
Rabies - Therapeutics under Development by Companies
Rabies - Therapeutics under Investigation by Universities/Institutes
Rabies - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Rabies - Products under Development by Companies
Rabies - Products under Investigation by Universities/Institutes
Rabies - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Celltrion, Inc.
CureVac GmbH
Humabs BioMed SA
Kaketsuken K.K.
Kamada Ltd.
Medicago Inc.
Molecular Targeting Technologies, Inc.
NanoViricides, Inc.
Novavax, Inc.
PaxVax
Prosetta Antiviral Inc.
Sanofi
Serum Institute of India Limited
Sinovac Biotech Ltd.
Trellis Bioscience, Inc.
VBI Vaccines Inc.
Zydus Cadila Healthcare Limited
Rabies - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CTP-19 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-7201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ebola + rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
human rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD-357 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Rabies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAV-866 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RabiCide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rabies virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rabimabs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SII RMab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SO-57 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOJB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VerorabVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rabies - Recent Pipeline Updates
Rabies - Dormant Projects
Rabies - Product Development Milestones
Featured News & Press Releases
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Rabies, H1 2015
Number of Products under Development for Rabies - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015
Rabies - Pipeline by Celltrion, Inc., H1 2015
Rabies - Pipeline by CureVac GmbH, H1 2015
Rabies - Pipeline by Humabs BioMed SA, H1 2015
Rabies - Pipeline by Kaketsuken K.K., H1 2015
Rabies - Pipeline by Kamada Ltd., H1 2015
Rabies - Pipeline by Medicago Inc., H1 2015
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H1 2015
Rabies - Pipeline by NanoViricides, Inc., H1 2015
Rabies - Pipeline by Novavax, Inc., H1 2015
Rabies - Pipeline by PaxVax, H1 2015
Rabies - Pipeline by Prosetta Antiviral Inc., H1 2015
Rabies - Pipeline by Sanofi, H1 2015
Rabies - Pipeline by Serum Institute of India Limited, H1 2015
Rabies - Pipeline by Sinovac Biotech Ltd., H1 2015
Rabies - Pipeline by Trellis Bioscience, Inc., H1 2015
Rabies - Pipeline by VBI Vaccines Inc., H1 2015
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Rabies Therapeutics - Recent Pipeline Updates, H1 2015
Rabies - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Rabies, H1 2015
Number of Products under Development for Rabies - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Beijing Minhai Biotechnology Co., Ltd
Celltrion, Inc.
CureVac GmbH
Humabs BioMed SA
Kaketsuken K.K.
Kamada Ltd.
Medicago Inc.
Molecular Targeting Technologies, Inc.
NanoViricides, Inc.
Novavax, Inc.
PaxVax
Prosetta Antiviral Inc.
Sanofi
Serum Institute of India Limited
Sinovac Biotech Ltd.
Trellis Bioscience, Inc.
VBI Vaccines Inc.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.